Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free ...

Recognizing TULSA is being used by urologists to treat an unrivalled variety of prostate cancer and/or BPH patients, Profound is developing a novel set of software modules under the TULSA-AI ® brand ...

Valley Health System says the new West Henderson Hospital will open Dec. 3 with 150 beds but has been master planned to ...

and the 25th Annual Meeting of the Society of Urologic Oncology taking place in Dallas, TX, December 4 – 6, 2024. The TULSA procedure, performed using Profound’s TULSA-PRO system, has the potential of ...

Investigators explored the role of treatment intensification with androgen receptor pathway inhibitors in patients with high-risk localized prostate cancer.

Deep learning with pose AI may offer a scalable, minimally invasive method for neuro-telemetry in the neonatal intensive care unit.

Prostate cancer is the second most commonly diagnosed cancer in men (behind skin cancer), with varying levels of ...

MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision ...

Younger and middle-aged patients seem to be disproportionately affected by neurologic manifestations of postacute sequelae of ...

UC Davis Comprehensive Cancer Center is the first in the region to offer a new groundbreaking clinical trial for bladder cancer patients. Previously ...

Compared with moderate or severe neurologic disabilities, complete neurologic recovery at hospital discharge following cardiac arrest is associated with better long-term survival. Complete neurologic ...

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated ...